Nevro Current Ratio 2013-2022 | NVRO

Nevro current ratio from 2013 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Nevro Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-06-30 $0.48B $0.07B 6.65
2022-03-31 $0.49B $0.07B 6.97
2021-12-31 $0.53B $0.08B 6.46
2021-09-30 $0.54B $0.08B 7.20
2021-06-30 $0.56B $0.07B 7.53
2021-03-31 $0.74B $0.25B 3.00
2020-12-31 $0.75B $0.24B 3.15
2020-09-30 $0.74B $0.24B 3.10
2020-06-30 $0.72B $0.22B 3.25
2020-03-31 $0.41B $0.06B 6.79
2019-12-31 $0.42B $0.07B 5.98
2019-09-30 $0.40B $0.07B 5.87
2019-06-30 $0.40B $0.07B 6.05
2019-03-31 $0.41B $0.07B 6.30
2018-12-31 $0.44B $0.06B 7.11
2018-09-30 $0.43B $0.05B 8.05
2018-06-30 $0.43B $0.05B 8.06
2018-03-31 $0.43B $0.05B 7.99
2017-12-31 $0.44B $0.06B 7.61
2017-09-30 $0.43B $0.05B 8.78
2017-06-30 $0.41B $0.04B 11.07
2017-03-31 $0.41B $0.03B 11.91
2016-12-31 $0.42B $0.04B 9.96
2016-09-30 $0.41B $0.04B 11.83
2016-06-30 $0.40B $0.03B 13.17
2016-03-31 $0.27B $0.03B 10.49
2015-12-31 $0.28B $0.04B 7.77
2015-09-30 $0.28B $0.02B 11.88
2015-06-30 $0.29B $0.02B 18.17
2015-03-31 $0.19B $0.01B 13.98
2014-12-31 $0.20B $0.01B 18.63
2014-09-30 $0.05B $0.01B 6.16
2014-06-30 $0.00B 0.00
2014-03-31 $0.00B 0.00
2013-12-31 $0.00B 0.00
2013-09-30 $0.00B 0.00
2012-12-31 $0.05B $0.01B 9.32
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $1.649B $0.387B
Nevro Corp. is a medical device company which engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg. The company is known for developing and commercializing the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Additionally, the company's HF10 therapy provides long-lasting relief from chronic back and leg pain. Nevro's flagship Senza SCS system has been consistently driving the top line. Since its commercial launch in the United States, the system raked in significant revenues. These apart, Senza is commercially available in Europe since 2010 and in Australia since 2011.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $198.711B 20.24
Edwards Lifesciences (EW) United States $51.226B 36.24
Alcon (ALC) Switzerland $28.513B 24.14
STERIS (STE) Ireland $16.630B 20.66
Teleflex (TFX) United States $9.450B 15.06
Fresenius Medical Care AG KGaA (FMS) Germany $8.228B 7.59
Penumbra (PEN) United States $7.184B 861.82
Globus Medical (GMED) United States $5.928B 30.24
Glaukos (GKOS) United States $2.520B 0.00
Integer Holdings (ITGR) United States $2.061B 16.12
Paragon 28 (FNA) United States $1.368B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.031B 15.78
Artivion (AORT) United States $0.558B 53.23